Product liability litigation regularly involves the highest stakes in cases of extreme complexity. Faced with such franchise-threatening matters, the world’s leading corporations trust Paul, Weiss to lead them to victory. Our superior ability to establish a winning, long-term strategy, our unique skill at breaking down and presenting complicated material, and our vaunted trial prowess make us counsel of choice in many of the most important product liability lawsuits.
'Insuring' the Continued Solvency of Pharmaceutical Companies in the Face of Product Liability Class Actions
March 14, 2005 Full PDF
In spring 2005, the Tort Trial & Insurance Practice Law Journal featured an article written by litigation associate Dr. Rochelle Chodock, David Yolkut and Dennis Connolly titled, "'Insuring' the Continued Solvency of Pharmaceutical Companies in the Face of Product Liability Class Actions." In the article, the authors propose a capitalistic plan to solve the economic and social consequences of product liability class actions on the pharmaceutical industry, the FDA and the public. The proposed plan uses natural checks and balances combined with economic incentives rather than government funding or increased judicial involvement to address pharmaceutical product liability suits.